Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus

J Diabetes Res. 2019 Nov 23:2019:8208237. doi: 10.1155/2019/8208237. eCollection 2019.

Abstract

Oxidative stress is enhanced by various mechanisms. Serum oxidized low-density lipoprotein (LDL) is a useful prognostic marker in diabetic patients with coronary artery disease. To examine the effects of Theracurmin®, a highly absorbable curcumin preparation, on glucose tolerance, adipocytokines, and oxidized LDL, we conducted a double-blind placebo-controlled parallel group randomized trial in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. We randomly divided the patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus and stable individuals into the placebo group and the Theracurmin® (180 mg daily for 6 months) group. Of the 33 patients analyzed, 18 (14 males and 4 females) were administered placebo and 15 (9 males and 6 females) were administered Theracurmin®. The patient characteristics did not differ between the two groups. The primary endpoint, HbA1c, did not differ significantly between the two groups. However, the level of α1-antitrypsin-low-density lipoprotein (AT-LDL), the oxidized LDL, significantly increased (p = 0.024) in the placebo group from the beginning of the trial up to 6 months, although there was no such change in the Theracurmin® group. The percentage change in BMI from the beginning of the trial up to 6 months tended to be higher in the Theracurmin® group than in the placebo group. Patients in the Theracurmin® group tended to have a larger percentage change in adiponectin and LDL-C than those in the placebo group. Patients in the Theracurmin® group showed a smaller percentage change in AT-LDL than those in the placebo group. This study suggests that the highly absorbable curcumin could potentially inhibit a rise in oxidized LDL in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. This trial is registered with UMIN000007361.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adiponectin / blood
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Antioxidants / administration & dosage*
  • Antioxidants / metabolism
  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Cholesterol, LDL / blood
  • Curcumin / administration & dosage*
  • Curcumin / metabolism
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Double-Blind Method
  • Female
  • Gastrointestinal Absorption*
  • Glucose Intolerance / blood
  • Glucose Intolerance / diagnosis
  • Glucose Intolerance / drug therapy*
  • Glycated Hemoglobin / metabolism
  • Humans
  • Japan
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Antioxidants
  • Biomarkers
  • Blood Glucose
  • Cholesterol, LDL
  • Glycated Hemoglobin A
  • Lipoproteins, LDL
  • hemoglobin A1c protein, human
  • oxidized low density lipoprotein
  • Curcumin